UB Paderborn / Katalog / Suche / in CDI

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia

Clinical cancer research, 2016-12, Vol.22 (23), p.5829-5838

2016

Link zum Volltext

Verfügbarkeit prüfen

Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies

Frontiers in oncology, 2017-05, Vol.7, p.100-100

2017

Link zum Volltext

Verfügbarkeit prüfen

Wheat and maize thioredoxins: A novel cross-reactive cereal allergen family related to baker's asthma

Journal of Allergy and Clinical Immunology, 2006-03, Vol.117 (3), p.676-681

2006

Link zum Volltext

Verfügbarkeit prüfen

Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells

Protein engineering, design and selection, 2017-09, Vol.30 (9), p.673-684

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5671: AFM26 - A novel CD16A-directed bispecific TandAb targeting BCMA for multiple myeloma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5671-5671

2017

Link zum Volltext

Verfügbarkeit prüfen

A rapid, sensitive and economical assessment of monoclonal antibody conformational stability by intrinsic tryptophan fluorescence spectroscopy

Biotechnology journal, 2008-10, Vol.3 (9-10), p.1201-1211

2008

Link zum Volltext

Verfügbarkeit prüfen

Identification of Borrelia burgdorferi Ribosomal Protein L25 by the Phage Surface Display Method and Evaluation of the Protein's Value for Serodiagnosis

Journal of Clinical Microbiology, 2006-10, Vol.44 (10), p.3778-3780

2006

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3641: EGFR/CD16A TandAbs are efficacious NK-cell engagers with favorable biological properties which potently kill EGFR+ tumors with and without Ras mutation

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3641-3641

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 593: Highly cytotoxic EGFRCD16A TandAbs specifically recruit NK cells to potently kill various types of solid tumors

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.593-593

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 593: Highly cytotoxic EGFR/CD16A TandAbs specifically recruit NK cells to potently kill various types of solid tumors

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.593-593

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 580: Anti-EGFRvIII TandAbs recruiting either T or NK cells are highly specific and potent therapeutic antibody candidates for the treatment of EGFRvIII+ tumors

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.580-580

2016

Link zum Volltext

Verfügbarkeit prüfen

EGFR/CD16A tetravalent bispecific antibody AFM24 to engage NK-cells to kill EGFR expressing tumor cells and safety results in cynomolgus monkey studies

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e14001-e14001

2017

Link zum Volltext

Verfügbarkeit prüfen

AFM26 is a novel, highly potent BCMA/CD16A-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.8045-8045

2017

Link zum Volltext

Verfügbarkeit prüfen

Trispecific Antibodies for Selective CD16A-Directed NK-Cell Engagement in Multiple Myeloma

Blood, 2016-12, Vol.128 (22), p.4513-4513

2016

Link zum Volltext

Verfügbarkeit prüfen

In Vitro and In Vivo Characterization of CD19/CD3 Tandab AFM11 and CD19/CD16A Tandab AFM12 Targeting NHL

Blood, 2015-12, Vol.126 (23), p.2763-2763

2015

Link zum Volltext

Verfügbarkeit prüfen

Unfolding and Double-stranded DNA Binding of the Cold Shock Protein Homologue Cla h 8 from Cladosporium herbarum

The Journal of biological chemistry, 2002-05, Vol.277 (19), p.16512-16516

2002

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2471: EGFRvIII T-cell TandAbs are specific and highly potent drug candidates for the treatment of a variety of solid tumors

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.2471-2471

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3753: Identification of antibodies against a novel tumor-associated MHC/peptide-target and generation of highly specific and potent HLA-A02MMP1-003/CD3 TandAbs

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3753-3753

2017

Link zum Volltext

Verfügbarkeit prüfen

Highly cytotoxic EGFR/CD16A TandAbs to recruit NK-cells to kill EGFR-expressing tumor cells

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e14007-e14007

2016

Link zum Volltext

Verfügbarkeit prüfen

Anti-EGFRvIII TandAbs recruiting either T- or NK-cells as bispecific therapeutic antibody candidates for the treatment of EGFRvIII+ tumors

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e14008-e14008

2016

Link zum Volltext

Verfügbarkeit prüfen

Construction and characterization of novel CD33/CD3 tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia (AML)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.7067-7067

2015

Link zum Volltext

Verfügbarkeit prüfen

Development of a bispecific tetravalent CD33/CD3 TandAbfor the treatment of AML

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.7071-7071

2015

Link zum Volltext

Verfügbarkeit prüfen

Fungal Allergies: A Yet Unsolved Problem

Allergy and Asthma in Modern Society: A Scientific Approach, 2006-01, Vol.91, p.121-133

2006

Link zum Volltext

Verfügbarkeit prüfen

Cloning allergens via phage display

Methods (San Diego, Calif.), 2004-03, Vol.32 (3), p.212-218

2004

Link zum Volltext

Verfügbarkeit prüfen

EGFRvIII TandAbs are specific and highly potent drug candidates for the treatment of solid tumors

Journal for immunotherapy of cancer, 2015-11, Vol.3 (Suppl 2), p.P219-P219, Article P219

2015

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia

Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies

Wheat and maize thioredoxins: A novel cross-reactive cereal allergen family related to baker's asthma

Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells

Abstract 5671: AFM26 - A novel CD16A-directed bispecific TandAb targeting BCMA for multiple myeloma

A rapid, sensitive and economical assessment of monoclonal antibody conformational stability by intrinsic tryptophan fluorescence spectroscopy

Identification of Borrelia burgdorferi Ribosomal Protein L25 by the Phage Surface Display Method and Evaluation of the Protein's Value for Serodiagnosis

Abstract 3641: EGFR/CD16A TandAbs are efficacious NK-cell engagers with favorable biological properties which potently kill EGFR+ tumors with and without Ras mutation

Abstract 593: Highly cytotoxic EGFRCD16A TandAbs specifically recruit NK cells to potently kill various types of solid tumors

Abstract 593: Highly cytotoxic EGFR/CD16A TandAbs specifically recruit NK cells to potently kill various types of solid tumors

Abstract 580: Anti-EGFRvIII TandAbs recruiting either T or NK cells are highly specific and potent therapeutic antibody candidates for the treatment of EGFRvIII+ tumors

EGFR/CD16A tetravalent bispecific antibody AFM24 to engage NK-cells to kill EGFR expressing tumor cells and safety results in cynomolgus monkey studies

AFM26 is a novel, highly potent BCMA/CD16A-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma

Trispecific Antibodies for Selective CD16A-Directed NK-Cell Engagement in Multiple Myeloma

In Vitro and In Vivo Characterization of CD19/CD3 Tandab AFM11 and CD19/CD16A Tandab AFM12 Targeting NHL

Unfolding and Double-stranded DNA Binding of the Cold Shock Protein Homologue Cla h 8 from Cladosporium herbarum

Abstract 2471: EGFRvIII T-cell TandAbs are specific and highly potent drug candidates for the treatment of a variety of solid tumors

Abstract 3753: Identification of antibodies against a novel tumor-associated MHC/peptide-target and generation of highly specific and potent HLA-A02MMP1-003/CD3 TandAbs

Highly cytotoxic EGFR/CD16A TandAbs to recruit NK-cells to kill EGFR-expressing tumor cells

Anti-EGFRvIII TandAbs recruiting either T- or NK-cells as bispecific therapeutic antibody candidates for the treatment of EGFRvIII+ tumors

Construction and characterization of novel CD33/CD3 tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia (AML)

Development of a bispecific tetravalent CD33/CD3 TandAbfor the treatment of AML

Fungal Allergies: A Yet Unsolved Problem

Cloning allergens via phage display

EGFRvIII TandAbs are specific and highly potent drug candidates for the treatment of solid tumors

Suchergebnisse filtern